Acumen Pharmaceuticals, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

The US FDA’s back-to-back approvals of Genentech ’s Tecentriq Hybreza and Ocrevus Zunovo place a spotlight on biologics delivery specialist Halozyme Therapeutics , whose Enhanze technology has now b

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lenz/Graphite Combination Is All-Stock

CARGO Therapeutics Inc. executed the 21st initial public offering in the US by a biopharmaceutical company in 2023 and the fifth-largest so far this year when it grossed $281.3m from an offering of 1